{"product_id":"qure-ansoff-analysis","title":"(QURE) uniQure N.V. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Ansoff Matrix Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis uniQure N.V. Ansoff Matrix Analysis maps growth options across market penetration, market development, product development, and diversification to help with research, strategy, or investment decisions; this page includes a real preview\/sample of the analysis so you can inspect style and substance before buying. Purchase the full version to receive the complete, ready-to-use company-specific Ansoff Matrix report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHOPE-B Phase III hemophilia B\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003euniQure is using etranacogene dezaparvovec to deepen its core hemophilia B position, and HOPE-B is the key Phase III proof point. In the pivotal trial, 54 adults with severe or moderately severe hemophilia B showed a median 54% factor IX activity at 24 months and a 77% bleed reduction, supporting stronger share gains in a rare-disease market. This is direct market penetration, not expansion into a new category.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAMT-060 hemophilia B Phase I\/II\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAMT-060 hemophilia B Phase I\/II gives uniQure a second program in the same rare-disease franchise, so it can deepen share where it already has the clearest focus. Hemophilia B affects about 1 in 25,000 male births, and that limited pool makes repeat presence in the same niche more valuable. By adding clinical depth to one of its most established areas, uniQure reinforces brand, data, and prescriber trust.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTwo hemophilia B gene therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003euniQure N.V. is concentrating on one disease: hemophilia B. AMT-061, now HEMGENIX, won FDA approval in 2022 and carries a U.S. list price of $3.5 million, while AMT-060 built earlier clinical know-how. This two-asset setup deepens medical awareness and supports faster uptake in a niche with about 1 in 30,000 male births.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRare severe genetic disease focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003euniQure N.V. keeps its market penetration tight by focusing on rare, severe genetic diseases where unmet need is highest. That niche fits its known treatment setting in hemophilia and other debilitating disorders, and it reinforces hard-won expertise in ultra-rare patients, specialist centers, and gene therapy delivery.\u003c\/p\u003e\n\u003cp\u003eThat is classic penetration: serve a defined buyer group more deeply instead of chasing broad demand. uniQure’s lead gene therapy, HEMGENIX, is already approved in the US for hemophilia B, giving the Company a real-world base to strengthen trust and repeat use in high-need rare disease markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocuses on ultra-rare, severe patients\u003c\/li\u003e\n\u003cli\u003eUses specialist treatment centers\u003c\/li\u003e\n\u003cli\u003eBuilds on hemophilia gene therapy know-how\u003c\/li\u003e\n\u003cli\u003eSupports deeper share in known markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAmsterdam-based specialist platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003euniQure N.V., founded in 1998 and headquartered in Amsterdam, uses its long operating history to deepen its gene therapy base rather than chase broad-market expansion. That 25+ year track record supports repeat use of its clinical, regulatory, and manufacturing know-how in the same focused niche.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1998 founding supports credibility\u003c\/li\u003e\n\u003cli\u003eAmsterdam HQ anchors specialist focus\u003c\/li\u003e\n\u003cli\u003eMarket penetration means depth, not breadth\u003c\/li\u003e\n\u003cli\u003eClinical continuity strengthens trust\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHEMGENIX Drives uniQure’s Hemophilia B Commercial Base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003euniQure’s market penetration centers on hemophilia B, where HEMGENIX gives the Company a commercial base in an ultra-rare niche. In HOPE-B, 54 adults had a 54% median factor IX activity at 24 months and a 77% bleed reduction, supporting deeper use in the same patient pool. HEMGENIX has a U.S. list price of $3.5 million.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHOPE-B patients\u003c\/td\u003e\n\u003ctd\u003e54\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFactor IX activity\u003c\/td\u003e\n\u003ctd\u003e54% at 24 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBleed reduction\u003c\/td\u003e\n\u003ctd\u003e77%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHEMGENIX U.S. list price\u003c\/td\u003e\n\u003ctd\u003e$3.5 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Ansoff Matrix framework for analyzing uniQure N.V.’s growth strategy\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear uniQure N.V. Ansoff Matrix snapshot to quickly align growth strategy across existing and new therapies and markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable list of primary sources validating uniQure N.V. growth-path assumptions for Ansoff Matrix analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAMT-130 Huntington’s disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003euniQure is using its AAV gene-therapy platform to move from rare-disease work into Huntington’s disease with AMT-130, now in Phase I\/II testing. That shifts an existing capability into a new therapeutic market, since Huntington’s affects about 1 in 7,000 people in the U.S. and has no curative treatment. Early clinical data support the market-development case, with 2026 attention centered on dose, safety, and huntingtin lowering.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAMT-210 Parkinson’s disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAMT-210 moves uniQure from hemophilia B into Parkinson’s disease, a much larger neurological market that affects about 10 million people worldwide. The program uses the same AAV gene-therapy platform, so it is a direct market-development play: one technology, a new patient base. If successful, it broadens uniQure’s addressable market beyond rare blood disorders and into a high-need CNS space.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAMT-260 temporal lobe epilepsy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAMT-260 is uniQure N.V.’s move into temporal lobe epilepsy, a new indication that expands its gene therapy platform into central nervous system disease. Epilepsy affects about 50 million people worldwide, and about 30% of patients remain drug-resistant, so the unmet need is large. This is market development: one tech, new disease market, bigger addressable pool.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAMT-161 ALS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAMT-161 marks uniQure N.V.’s move into amyotrophic lateral sclerosis, showing the company is taking its gene therapy platform into another severe neurodegenerative field. ALS is rare but deadly, with about 5,000 new U.S. cases each year and median survival of 2 to 5 years after diagnosis. That makes this a clear market development step, not just a product tweak.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew clinical field: ALS\u003c\/li\u003e\n\u003cli\u003ePlatform reused in a severe unmet-need market\u003c\/li\u003e\n\u003cli\u003eHigh-risk, high-value expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAMT-240 autosomal dominant Alzheimer’s disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAMT-240 is an early preclinical move by uniQure N.V. into autosomal dominant Alzheimer’s disease, a rare, genetically defined market that sits far outside its hemophilia base. ADAD is under 1% of Alzheimer’s cases, so this is a small but high-value entry point for a first-in-class gene therapy. If it works, it broadens uniQure’s reach from rare bleeding disorders into neurodegeneration.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePreclinical first step\u003c\/li\u003e\n\u003cli\u003eNew Alzheimer’s market\u003c\/li\u003e\n\u003cli\u003eRare, gene-driven target\u003c\/li\u003e\n\u003cli\u003eDiversifies beyond hemophilia\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003euniQure Expands Its AAV Platform Into Massive CNS Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003euniQure N.V. is using one AAV platform to enter new CNS markets: Huntington’s, Parkinson’s, epilepsy, ALS, and preclinical ADAD. These are true market-development bets because the tech is reused while the patient base expands. The biggest pools are Parkinson’s at about 10 million people worldwide and epilepsy at about 50 million.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eNew market\u003c\/th\u003e\n\u003cth\u003eStage\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAMT-130\u003c\/td\u003e\n\u003ctd\u003eHuntington’s\u003c\/td\u003e\n\u003ctd\u003ePhase I\/II\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAMT-210\u003c\/td\u003e\n\u003ctd\u003eParkinson’s\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAMT-260\u003c\/td\u003e\n\u003ctd\u003eEpilepsy\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003euniQure N.V. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEtranacogene dezaparvovec AMT-061\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEtranacogene dezaparvovec AMT-061 is uniQure N.V.'s lead gene therapy and its most advanced program, anchored by the HOPE-B Phase III trial in hemophilia B. It fits Ansoff product development: a new therapy for an existing disease market, aiming at patients needing durable factor IX control. In HOPE-B, the company reported sustained factor IX activity and a 64% annualized bleed-rate reduction versus lead-in.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAMT-060 hemophilia B follow-on\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAMT-060 adds product depth in uniQure N.V.’s core hemophilia B franchise, targeting the same market as its later-stage gene therapy. In Phase I\/II, it serves as an earlier follow-on asset that can widen the company’s clinical and commercial options without leaving the FIX defect space. That matters in a market where even FIX activity above 5% can cut severe bleeding risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase III to Phase I\/II pipeline ladder\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003euniQure N.V. runs a laddered pipeline from Phase I\/II into Phase III, with multiple rare-disease gene therapy programs instead of a single-asset bet. That setup supports repeat product creation in the same niche market, which fits an Ansoff product-development move. Its late-stage asset HEMGENIX also gives commercial proof while newer candidates progress through the clinic.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHemophilia B product family\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003euniQure N.V.’s hemophilia B franchise is a true product-development story: AMT-061, now etranacogene dezaparvovec (Hemgenix), is the lead asset, while AMT-060 is the earlier-stage predecessor in the same disease area. Hemgenix showed a 54% mean factor IX activity at 104 weeks in HOPE-B, supporting one franchise built on the same biology.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAMT-061: lead hemophilia B gene therapy\u003c\/li\u003e\n\u003cli\u003eAMT-060: earlier-stage hemophilia B asset\u003c\/li\u003e\n\u003cli\u003eSame disease franchise, lower R\u0026amp;D risk\u003c\/li\u003e\n\u003cli\u003eHOPE-B: 54% mean FIX activity at 104 weeks\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical-stage innovation engine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003euniQure keeps turning research into product candidates, with a clinical pipeline built around AMT-130, AMT-191, and AMT-260 across severe genetic diseases. That repeatable engine matters in Ansoff terms: it deepens product development inside markets that already need one-time gene therapies. As of 2025, uniQure had 3 clinical-stage assets, showing the platform is not a one-off.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3 clinical-stage programs\u003c\/li\u003e\n\u003cli\u003eTargets severe genetic disease markets\u003c\/li\u003e\n\u003cli\u003ePlatform supports repeat launches\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003euniQure's Hemophilia B Gene Therapy Pipeline Gains Momentum\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003euniQure N.V.'s product development strategy centers on hemophilia B gene therapy, led by etranacogene dezaparvovec AMT-061, which posted 54% mean factor IX activity at 104 weeks in HOPE-B. AMT-060 deepens the same disease franchise, while AMT-130, AMT-191, and AMT-260 show repeat pipeline creation. As of 2025, uniQure had 3 clinical-stage programs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStage\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAMT-061\u003c\/td\u003e\n\u003ctd\u003ePhase III\u003c\/td\u003e\n\u003ctd\u003e54% mean FIX at 104 weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAMT-060\u003c\/td\u003e\n\u003ctd\u003ePhase I\/II\u003c\/td\u003e\n\u003ctd\u003eSame hemophilia B market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline\u003c\/td\u003e\n\u003ctd\u003e3 clinical-stage\u003c\/td\u003e\n\u003ctd\u003eAMT-130, AMT-191, AMT-260\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMultiple CNS programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003euniQure N.V. is diversifying into 4 CNS programs outside hemophilia B: AMT-130, AMT-210, AMT-260, and AMT-161. This is a move into several central nervous system markets at once, spreading risk across different diseases and biology. In 2025, that portfolio mix gives uniQure more shots at value beyond a single hemophilia franchise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHuntington’s, Parkinson’s and epilepsy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003euniQure N.V. is diversifying into 3 distinct CNS markets: Huntington’s disease with AMT-130, Parkinson’s disease with AMT-210, and epilepsy with AMT-260. This is not one-disease expansion; each asset hits a different neurological target, which can spread clinical and commercial risk. That helps reduce dependence on the hemophilia B franchise and builds a broader long-term revenue base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eALS and Alzheimer’s disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003euniQure N.V. is using AMT-161 and AMT-240 to enter two new neurodegenerative markets: ALS and autosomal dominant Alzheimer’s disease. ALS affects about 30,000 people in the United States at any time, while autosomal dominant Alzheimer’s disease is rare, at roughly 1% of Alzheimer’s cases. This is a true new-products, new-markets move in the Ansoff Matrix, aimed at severe unmet need.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePreclinical to Phase III spread\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003euniQure’s pipeline spans preclinical AMT-240 through Phase III HOPE-B, so the company is not tied to one development bet. That spread diversifies risk across early, mid, and late-stage assets, while also opening multiple future market shots if one program advances faster than others.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePreclinical AMT-240 adds early optionality.\u003c\/li\u003e\n\u003cli\u003ePhase III HOPE-B adds late-stage value.\u003c\/li\u003e\n\u003cli\u003eSpread lowers single-asset dependence.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRare-disease portfolio breadth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003euniQure is diversified across 6 severe indications, not one market: hemophilia B, Huntington’s disease, Parkinson’s disease, epilepsy, ALS, and Alzheimer’s disease. That breadth shows a rare-disease platform built on gene therapy science, with multiple shots on goal across blood and CNS disorders. It is not a single-product story.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e6 indications across 2 major disease areas\u003c\/li\u003e\n\u003cli\u003eBroad rare-disease platform, not one market\u003c\/li\u003e\n\u003cli\u003eMultiple pipeline shots on goal\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003euniQure’s 4 CNS Bets Diversify Risk Across 6 Indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003euniQure N.V. is using diversification in the Ansoff Matrix by pushing 4 CNS programs beyond hemophilia B: AMT-130, AMT-210, AMT-260, and AMT-161. That spreads clinical risk across 6 indications and gives the company more than one path to value in 2025\/2026.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCNS programs\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndications\u003c\/td\u003e\n\u003ctd\u003e6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234857623817,"sku":"qure-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/qure-ansoff-matrix.webp?v=1785729643","url":"https:\/\/dcfanalyst.com\/products\/qure-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}